News
-
-
-
COMMUNIQUÉ DE PRESSE
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development -
-
-
-
COMMUNIQUÉ DE PRESSE
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva announces half-year liquidity contract review with Kepler Cheuvreux. Cash and shares available in the liquidity account disclosed. Company focuses on developing oral small molecule therapies for MASH and unmet medical needs -
COMMUNIQUÉ DE PRESSE
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Inventiva publie son bilan semestriel du contrat de liquidité avec Kepler Cheuvreux. Espèces de 349 630,55 € et 113 452 actions Inventiva au 31/12/2024. Analyse des transactions du semestre. Entreprise biopharmaceutique axée sur la stéatohépatite et autres maladies -
-
